Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects-Reference-Cited by-同舟云学术

Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects

Published:2023-02-17 Issue:2 Volume:41 Page:276-283
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Hu Linlin,Dou Ting,Sun Qiuyue,Tang Lu,Cai Mingmin,Qian Wei,Wang Huiping

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01331-0.pdf

Reference17 articles.

1. Slade D (2020) PARP and PARG inhibitors in cancer treatment. Genes Dev 34(5–6):360–394. https://doi.org/10.1101/gad.334516.119

2. Lee A (2021) Fuzuloparib: first approval. Drugs 81(10):1221–1226. https://doi.org/10.1007/s40265-021-01541-x

3. Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L (2019) Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 110(3):1064–1075. https://doi.org/10.1111/cas.13947

4. Li N, Liu Q, Tian Y, Wu L (2022) Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. J Gynecol Oncol 33(6):e86. https://doi.org/10.3802/jgo.2022.33.e86

5. Wu M, Li X, Sun J, Chen H, Ding Y (2021) A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy chinese volunteers. Expert Opin Drug Metab Toxicol 17(4):503–508. https://doi.org/10.1080/17425255.2021.1881480

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors;Cancer Chemotherapy and Pharmacology;2024-06-15

2. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers;Cancer Chemotherapy and Pharmacology;2024-05-04